Shareholders representing more than 20% of all shares and votes in Pharmacolog have announced that at the Annual General Meeting on April 29, 2019, they will propose a new board.
The proposal proposes re-election of Erik Hedlund (chairman) and Olof Johansson and new election of Carl-Johan Spak and Ragnar Linder.
All the proposed members have a long industrial background, many years of experience as entrepreneurs and relevant industry knowledge. The additions to the Board mean that the composition well represents the competencies that the company needs, to develop its commercial activities and develop new innovations.
Carl-Johan Spak, born 1956, is Senior Vice President of Recipharm AB with responsibility for strategic investments and special projects. Carl-Johan has been employed in senior positions at Recipharm since 2009, with responsibility for, among other things, its overall development activities. Prior to that, Carl-Johan has served as head of Meda’s Nordic organization and CEO of Recip AB. He is currently engaged as a board member in a number of different life science companies both in Sweden and internationally. Carl-Johan has a basic education as a dentist and a PhD in cariology and pharmacology at Karolinska Institutet in 1984.
Ragnar Linder, born 1953, holds a Master of Science in Chemical Engineering from KTH. Ragnar is co-founder of Pygargus, a research company in the field of Real World Evidence, which was purchased by IMS Health (now IQIVIA) in 2013 and where Ragnar has since held senior positions. Ragnar has also held several senior positions at Amgen Nordic (CEO) Aventis, HMR and Hoechst. Furthermore, Ragnar has been a board member of several biotech pharmaceutical and CRO companies.
Mats Högberg resigns from the Board but remains as the company’s CEO. Founder Hans Dahlin leaves the board but continues to work in the company and the management team as responsible for Innovation and Research. Furthermore, Hans will assist the Board in product strategic issues.
Of the persons proposed for new elections, both Carl-Jona Spak and Ragnar Linder, are independent of the Company, company management and major shareholders in the Company.
For more information contact:
Mats Högberg, CEO
Phone: +46 70-546 50 21
About Pharmacolog AB
Pharmacolog is specialized in developing systems and solutions for more effective and safer use of intravenous drugs. The company’s first product, DrugLog®, enables a nurse or pharmacist to quickly and easily verify that an injectable drug has the right identity and concentration. Pharmacolog’s long-term vision is an individually optimized medication for each individual patient, considering all available parameters in the control and distribution of the drug. Further information regarding the company is available at http://www.pharmacolog.com. The company’s Certified Adviser is Mangold Fondkommission AB, which can be reached on telephone number +46 8-5030 15 50 or through CA@mangold.se.
Download as PDF